binosto Drug Patent Profile

✉ Email this page to a colleague

When do Binosto patents expire, and when can generic versions of Binosto launch?

Binosto is a drug marketed by Radius and is included in one NDA. There is one patent protecting this drug.

This drug has twenty patent family members in sixteen countries.

The generic ingredient in BINOSTO is alendronate sodium. There are twenty-five drug master file entries for this compound. Twenty-two suppliers are listed for this compound. Additional details are available on the alendronate sodium profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Binosto

A generic version of binosto was approved as alendronate sodium by APOTEX on August 4^th, 2008.

Sign Up

AI Research Assistant

Questions you can ask:

What is the 5 year forecast for binosto?
What are the global sales for binosto?
What is Average Wholesale Price for binosto?

Summary for binosto

International Patents:	20
US Patents:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	57
Clinical Trials:	3
Patent Applications:	82
Drug Prices:	Drug price information for binosto
What excipients (inactive ingredients) are in binosto?	binosto excipients list
DailyMed Link:	binosto at DailyMed

Drug patent expirations by year for binosto

Recent Clinical Trials for binosto

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Doris Duke Charitable Foundation	Phase 2
University of California, Davis	Phase 2
National Heart, Lung, and Blood Institute (NHLBI)	Phase 2

See all binosto clinical trials

Pharmacology for binosto

Drug Class	Bisphosphonate

US Patents and Regulatory Information for binosto

binosto is protected by one US patents.

Patents protecting binosto

Stable effervescent bisphosphonate formulations with rapid solubilization characteristics
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Radius	BINOSTO	alendronate sodium	TABLET, EFFERVESCENT;ORAL	202344-001	Mar 12, 2012		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up	Y			⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for binosto

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Radius	BINOSTO	alendronate sodium	TABLET, EFFERVESCENT;ORAL	202344-001	Mar 12, 2012	⤷ Sign Up	⤷ Sign Up
Radius	BINOSTO	alendronate sodium	TABLET, EFFERVESCENT;ORAL	202344-001	Mar 12, 2012	⤷ Sign Up	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

International Patents for binosto

See the table below for patents covering binosto around the world.

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
Australia	2003219999	EFFERVESCENT COMPOSITIONS COMPRISING BISPHOSPHONATES AND METHODS RELATED THERETO	⤷ Sign Up
Denmark	2648702		⤷ Sign Up
Australia	2003284275	EFFERVESCENT COMPOSITIONS COMPRISING BISPHOSPHONATES AND METHODS RELATED THERETO	⤷ Sign Up
Russian Federation	2608724	СТАБИЛЬНЫЕ СОСТАВЫ ШИПУЧЕГО БИСФОСФОНАТА СО СВОЙСТВАМИ БЫСТРОЙ СОЛЮБИЛИЗАЦИИ (STABLE FORMULATIONS OF EFFERVESCENT BISPHOSPHONATE WITH PROPERTIES OF FAST SOLUBILIZATION)	⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration

Supplementary Protection Certificates for binosto

Subscribe to access the full database, or Sign Up
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1175904	2007C/048	Belgium	⤷ Sign Up	PRODUCT NAME: ALENDRONATE DE SODIUM/COLECALCIFEROL; AUTHORISATION NUMBER AND DATE: EU/1/05/310/001 20050826
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description